Trending Now
High-frequency trading during the holiday season
There always exists a conflict between investors and traders. One extracts inefficiencies in transactions while the other attempts to define value. Technological...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Zai Lab Limited (NASDAQ: ZLAB) Reports Revenue of $36.9 Million Inn...
Zai Lab Limited (NASDAQ: ZLAB) has announced its Q2 2021 financial results and offered to cooperate updates and recent product highlights.
Zai Lab posted revenue...
MAKE IT MODERN
LATEST REVIEWS
Covid Stocks Could Represent Huge Value on Sale (NVAX, OTLC, PFE,...
Just when we started to think it was over, Omicron popped up and reminded us that this thing is a whole lot...
MAKE IT MODERN
PERFORMANCE TRAINING
How to Play the Next Bitcoin Squeeze (MARA, ISWH, OSTK, SQ, PYPL, BITF, CAN,...
Lost in the turmoil of the risk asset correction taking place so far in 2022 could be a huge opportunity to get...
Why the EV Pullback Could be a Once-in-a-Lifetime Opportunity for Investors (TSLA, DSGT, XPEV,...
If there’s one stat that really shows the growth potential in the electric vehicle space over coming years, it’s this: EVs accounted...
The FDA Has Lifted A Hold on Clinical Trials for an Experimental CymaBay Therapeutics...
In November 2019, CymaBay Therapeutics Inc. (NASDAQ:CBAY) received the most disappointing news, which had the potential of disrupting its operations. The FDA had frozen...
Monopar Therapeutics Inc. (NASDAQ: MNPR) Doses First Advanced Soft Tissues Sarcoma Patient In Study...
Monopar Therapeutics Inc. (NASDAQ: MNPR) has doses the first patient in the dose-escalation, open-label phase 1b clinical study evaluating camsirubicin in advanced soft tissues...
Novavax, Inc. (NASDAQ:NVAX) Signs a Development and Commercial Collaboration with Serum Institute for a...
More often than not, the most vulnerable countries are usually forgotten when it comes to the distribution of new treatments. This should not be...
MAKE IT MODERN
